SCHEMBL4238065

SCHEMBL4238065

O=c1c2ccccc2nc(-c2ccccc2F)n1NCc1ccc(F)cc1F

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.65
MDM2 Q00987 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.57
NPSR1 Q6W5P4 4/20 0.49
HPGD P15428 1/20 0.49
LMNA P02545 3/20 0.46
TSHR P16473 2/20 0.46
GAA P10253 1/20 0.46
MAPK1 P28482 1/20 0.46
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
APAF1 O14727 1/20 0.46
NPC1 O15118 1/20 0.46
MITF O75030 1/20 0.46
HSP90AA1 P07900 1/20 0.46
IDO1 P14902 1/20 0.46
TDO2 P48775 1/20 0.46
RAB9A P51151 1/20 0.46
IDO2 Q6ZQW0 1/20 0.46
GLA P06280 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4240089 0.90 ALDH1A1 (0.56) ALDH1A1MDM2SMN1; SMN2NPSR1HPGD
SCHEMBL4237530 0.88 SMN1; SMN2 (0.73) ALDH1A1MDM2SMN1; SMN2NPSR1HPGD
SCHEMBL4245933 0.87 ALDH1A1 (0.51) ALDH1A1MDM2SMN1; SMN2NPSR1HPGD
SCHEMBL4236257 0.86 ALDH1A1 (0.70) ALDH1A1MDM2SMN1; SMN2NPSR1HPGD
SCHEMBL4237239 0.86 SMN1; SMN2 (0.61) ALDH1A1MDM2SMN1; SMN2NPSR1HPGD
SCHEMBL4236094 0.84 ALDH1A1 (0.62) ALDH1A1MDM2SMN1; SMN2NPSR1HPGD
SCHEMBL4238052 0.84 ALDH1A1 (0.62) ALDH1A1MDM2SMN1; SMN2NPSR1HPGD
SCHEMBL4239817 0.81 ALDH1A1 (0.61) ALDH1A1MDM2SMN1; SMN2NPSR1HPGD
SCHEMBL4237386 0.80 LMNA (0.53) ALDH1A1MDM2SMN1; SMN2NPSR1HPGD
SCHEMBL4241360 0.80 ALDH1A1 (0.62) ALDH1A1MDM2SMN1; SMN2NPSR1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 GRK5, PLAAT5, GPBAR1 ALDH1A1 3192/4885MDM2 4740/4885SMN1; SMN2 4767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.